Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genetic Variant Protects People Against Malaria

08.11.2002


An international team of scientists has discovered a novel genetic trait that protects its carriers against the deadliest forms of malaria, while people without the trait are more likely to succumb to its fatal consequences.



This trait -- a mutation or “polymorphism” in the NOS2 gene -- controls the production of nitric oxide, a small chemical that can kill parasites and prevent malaria disease. Results of their study are published in the Nov. 9, 2002, issue of The Lancet.

The genetic variant explains why some people with malaria have only mild symptoms and recover fully, while others develop severe disease that may progress to death, said researchers from the University of Utah, the Durham Veterans Affairs (VA) Medical Center, Duke University Medical Center, the U.S. Centers for Disease Control and Prevention, Tanzania and Kenya.


“Malaria is a worldwide epidemic, affecting twice the population of the United States every year,” said Brice Weinberg, M.D., professor of medicine at the Durham VA and Duke University Medical Centers and principal investigator on the study. “Drug resistance to malaria is rampant, so our ability to artificially duplicate the benefits of this genetic trait would be enormous.”

People with the NOS2 gene variant make higher levels of nitric oxide, and the nitric oxide protects them from the extensive tissue and brain damage normally caused by the malaria parasite, said Dr. Maurine Hobbs, lead author and research assistant professor of internal medicine and human genetics at the University of Utah.

The team’s ultimate goal is to develop a simple treatment that boosts levels of nitric oxide to treat and prevent malaria, a prospect that the researchers say is well within their grasp.

Nitric oxide works by reducing the malaria parasites’ ability to multiply in liver and blood cells, preventing infected red blood cells from adhering to the lining of blood vessels, and decreasing the production of inflammatory chemicals (cytokines) that exacerbate the disease. Thus, it reduces the most deadly effects of malaria, which target the blood and vital organs such as the brain, said Dr. Nick Anstey, associate professor of medicine at the Menzies School for Health Research in Darwin, Australia.

While excessive nitric oxide can be harmful and causes inflammation in diseases such as arthritis, Anstey said that nitric oxide can also be beneficial by protecting against infections and preventing damage to cells and organs.

“Nitric oxide can be extremely useful when it is produced by the right cells, at the right levels, and at the right time,” said Anstey. Interestingly, he noted, the NOS2 gene variant does not prevent malarial infection; it simply renders the malaria parasite less harmful to bodily systems.

In fact, the NOS2 gene variant confers such overwhelming protection that Tanzanian carriers have an 88 percent lower risk of becoming ill with malaria than those without the trait, the study showed. In Kenya, its carriers have a 75 percent lower rate of developing severe malarial anemia. The two groups of patients consisted of 1,291 children who lived in highly mosquito- and malaria-infested areas of the two countries. The researchers analyzed blood and urine samples to demonstrate that people with the NOS2 polymorphism had higher levels of nitric oxide.

Weinberg said they believe that evolution has favored this protective mechanism for individuals who are most often exposed to malaria. Not surprisingly, then, Caucasians do not possess this genetic mutation, so they are at much higher risk for severe malaria. While malaria is seemingly a remote possibility in the heartland of America, the disease was once prevalent in the parts of the U.S. It was virtually eliminated by the 1940s through better mosquito control and improved living conditions, yet the disease periodically emerges in the U.S., even today.

Only about 1,200 malaria cases are reported in the U.S. yearly, and it is unlikely to ever reach epidemic proportions here, but malaria is rampant in much of Africa and Asia, infecting about 500 million people each year. Despite some advances in treatment, malaria continues to be deadly -- a malaria death occurs every 30 seconds worldwide.

Many of those infected with the malaria parasite may have no symptoms or only mild flu-like symptoms. However, others progress to more severe disease with extreme fatigue, fever, and chills. A third of these victims with severe disease -- mostly children and pregnant women -- succumb to more deadly consequences, either cerebral malaria or severe anemia.

In cerebral malaria, red blood cells containing the malaria parasite stick to the lining of blood vessels, causing blockages and decreasing blood supply to parts of the brain. Up to one-third of children with cerebral malaria die despite treatment. In severe anemia, parasites gobble up hemoglobin, destroy red blood cells and block blood formation until the patient is beyond rescue. Even with the best of current treatments, more than 1 million people die each year of severe malaria. The newly identified NOS2 gene polymorphism -- called C-1173T NOS2 -- protects against both kinds of malaria.

In addition to investigators from Duke, Utah, Australia and the CDC, researchers from the Hubert Kairuki Memorial University in Tanzania, and the World Health Organization in Switzerland contributed to the work. The research was supported by the National Institutes of Health, the U.S. Veterans Affairs, the U.S. Agency for International Development and the U.S. Centers for Disease Control and Prevention.

Rebecca Levine | EurekAlert!
Further information:
http://dukemednews.org/news/article.php?id=6008
http://www.mc.duke.edu/

More articles from Health and Medicine:

nachricht Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Electrical 'switch' in brain's capillary network monitors activity and controls blood flow

27.03.2017 | Health and Medicine

Clock stars: Astrocytes keep time for brain, behavior

27.03.2017 | Life Sciences

Sun's impact on climate change quantified for first time

27.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>